X

Trial Profile

A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Oct 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Respiratory syncytial virus vaccine Pfizer (Primary)
Indications Respiratory syncytial virus infections
Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
Acronyms RENOIR
Sponsors Pfizer

Most Recent Events

11 Sep 2024 Planned number of patients changed from 37630 to 45000.
11 Sep 2024 Status changed from active, no longer recruiting to recruiting.
10 Jul 2024 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com